Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, maraviroc (Celsentri®) cannot be endorsed for use within NHS Wales in combination with other antiretroviral medicinal products for treatment-experienced adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable. |
||
|
||
Medicine details |
||
| Medicine name | maraviroc (Celsentri®) | |
| Formulation | 25 mg, 75 mg, 150 mg and 300 mg film-coated tablet and 20 mg/ml oral solution | |
| Reference number | 3511 | |
| Indication | In combination with other antiretroviral medicinal products for treatment-experienced adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable. |
|
| Company | ViiV Healthcare UK Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 26/10/2017 | |